FDA clearance for ritonavir in children with AIDS.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000293:Adolescent; D019380:Anti-HIV Agents / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016049:Didanosine / Q000008:administration & dosage; D017277:Drug Approval; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D019438:Ritonavir / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration; D015215:Zidovudine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D015215:Zidovudine; D016049:Didanosine; D019438:Ritonavir